A phase I/IIa study of VS-7375
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs GFH 375 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 21 Jan 2025 New trial record
- 14 Jan 2025 According to Verastem Oncology media release, the company anticipates filling a U.S. IND application during Q1 of 2025 and expects to initiate this phase I/IIa study in mid of 2025.